Going down the list of stocks in the IBB, my next stop was United Therapeutics (UTHR). I spent about a day doing research and wrote up my conclusions for Seeking Alpha:United Therapeutics Appears UndervaluedI concluded I did not want to buy UTHR at the present time. Buying it a year ago would have been smart, but then a lot of […]
10 Best Biotech Stocks To Buy Right Now: Lpath Inc (LPTN)Lpath, Inc. (Lpath), incorporated on September 18, 2002, is a biotechnology company focused on the discovery and development of bio-active lipid-targeted monoclonal antibody (mAb) therapeutics. The Company has three product candidates, iSONEP, ASONEP and Lpathomab. The Company’s program, iSONEP, is a mAb against Sphingosine-1-Phosphate (S1P). As of December 31, 2012, […]
Source: Gilead Sciences.Gilead Sciences surprised investors when it recently announced that it will begin returning some of its cash stockpile to investors in the form of a dividend. Since dividend-paying biotech stocks are a bit of a rarity, we asked two Motley Fool healthcare experts for their opinion on whether Gilead Sciences’ dividend plan makes sense. Read on to learn […]
There may be no other industry as prone to hit-or-miss investments as biotechnology. An astounding 90% of drugs that enter phase 1 clinical trials never reach commercialization, and that means failure is far more common than success. As a result, many biotech companies research a slate of drugs in hopes of having at least one pan out. That’s not the […]
Rise in oil prices, new deals and upbeat quarterly results helped benchmarks settle in the green on Thursday. While rise in crude oil prices fueled gains in material and energy shares, Pfizer’s plan to acquire Hospira boosted healthcare stocks. Encouraging earnings results from O’Reilly Automotive and Estée Lauder Cos also added to the bullish sentiment. Meanwhile, investors shrugged off discouraging […]
“We have a habit of looking at crude as a barometer for global economic growth,” said Art Hogan, chief market strategist at Wunderlich Securities. Regressive analysis by his firm showed that for the last 25 years the S&P 500 has only had a 0.03 correlation with crude. That correlation has jumped to 0.7 since crude began its plunge last June.Among […]
High-frequency trading (HFT) firms make money – and lots of it – by exploiting inefficiencies in the pricing of shares quoted on several exchanges in an increasingly fragmented marketplace. They also generate significant income by capturing rebates offered by various exchanges for providing liquidity. While detractors dub such practices as abusive and predatory – claiming, for instance, that HFT firms […]
Benchmarks ended a narrow trading session in the green on Monday, boosted by gains in Internet, bio-tech and small-cap stocks. However, developments on the deals front were mixed, limiting the Dow’s gains. While AT&T agreed to acquire DirecTV, Pfizer’s final bid was rejected by AstraZeneca. As the day was devoid of any major economic data, investors focused their attention on […]
By Anora Mahmudova, MarketWatch
[…]
Benchmarks were finally able to close in the green yesterday, helped by some encouraging corporate numbers. Gains from pharma major Pfizer also helped benchmarks notch up a rare win, which came a day after benchmarks had suffered their biggest losses since last June. Discretionary stocks led the gains for the S&P 500’s industry groups.For a look at the issues currently […]
